Larvol Delta - ASLAN-Pharmaceuticals-to-Present-Additional-Data-From-Interim-Analysis-of-TREKDX-Phase-2-Study-of-Eblasakimab-in-DupilumabExperienced-Atopic-Dermatitis-Patients-During-Virtual-KOL-Event

eblasakimab (ASLAN004) - ASLAN Pharma, Zenyaku Holdings

https://www.globenewswire.com/news-release/2024/05/07/2876615/0/en/ASLAN-Pharmaceuticals-to-Present-Additional-Data-From-Interim-Analysis-of-TREK-DX-Phase-2-Study-of-Eblasakimab-in-Dupilumab-Experienced-Atopic-Dermatitis-Patients-During-Virtual-KO.html

May 7, 2024

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next